- Home
- C vs NVO Comparison
C vs NVO Comparison
Compare C & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | C | NVO |
|---|---|---|
| Founded | 1812 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8B | 212.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | C | NVO |
|---|---|---|
| Price | $118.05 | $62.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 10 |
| Target Price | ★ $123.79 | $54.25 |
| AVG Volume (30 Days) | 15.4M | ★ 20.8M |
| Earning Date | 01-14-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.03% | 1.97% |
| EPS Growth | ★ 17.63 | 10.06 |
| EPS | ★ 6.99 | 3.67 |
| Revenue | ★ $75,716,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $19.93 | $7.25 |
| Revenue Next Year | $3.61 | $0.24 |
| P/E Ratio | $16.88 | ★ $16.45 |
| Revenue Growth | 6.10 | ★ 16.64 |
| 52 Week Low | $55.51 | $43.08 |
| 52 Week High | $124.17 | $93.80 |
Technical Indicators
Market Signals| Indicator | C | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 72.64 |
| Support Level | $110.47 | $56.29 |
| Resistance Level | $118.75 | $60.63 |
| Average True Range (ATR) | 2.92 | 1.44 |
| MACD | -0.98 | 0.59 |
| Stochastic Oscillator | 53.81 | 96.28 |
Price Performance
Historical ComparisonAbout C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.